51 results about "Proteoglycan" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention relates to the technical field of functional nutritious food, in particular to multi-layer skin nutrition powder with a whole-spectrum skin growth and repair promoting effect and a preparation method and application thereof, the core of the multi-layer skin nutrition powder is composed of a collagen peptide system (60-62%), a proteoglycan system (20-22%) and the like, collagen peptide is compounded with three sources of cattle, fish and chicken, and the multi-layer skin nutrition powder has the advantages that the multi-layer skin nutrition powder is prepared; according to the present invention, with the combination of the following components, the skin structure and activity are jointly promoted by using the synergistic effect of the functional polypeptide compound (2.5-3.5%) and the plant active component (3.5-4.5%) rich in asiaticoside and procyanidine, and the nutrition enhancers (4-5%) such as L-ascorbic acid and amino acid chelated zinc and the food-grade auxiliary materials (8-10%) such as microcrystalline cellulose are integrated in the formula, such that the various systems achieve the synergistic effect so as to achieve the effect of nourishing the skin; through the synergistic compatibility of the three-source collagen peptide, the comprehensive supplement of various types of collagen in skin tissues is realized.

This invention belongs to the field of functional food processing technology, specifically relating to a method for improving the flavor of a chlorophyll-deficient Chlorella proteoglycan mutant. The method includes the following steps: S1, obtaining a Chlorella proteoglycan mutant strain; S2, centrifuging the Chlorella proteoglycan mutant strain and collecting the algal sludge, then pulverizing the collected algal sludge and dispersing it in water to obtain an algal powder suspension, then adding a compound enzyme to the algal powder suspension, and inactivating the enzyme after the reaction; S3, cooling the system to room temperature, adding glucose and stirring to dissolve, sterilizing, inoculating with a compound bacterial strain and fermenting, and sterilizing again after fermentation; S4, cooling the fermented system to room temperature, then adding β-cyclodextrin and stirring, and drying the system after stirring to obtain the algal protein product. This invention employs a synergistic process of compound enzymatic hydrolysis, compound bacterial fermentation, and β-cyclodextrin encapsulation to remove the off-flavor of the mutant algae from the source, significantly improving the flavor and enhancing the product's storage stability.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of oleanolic acid in promoting chondrogenic differentiation of chondrocytes. This invention discovers that oleanolic acid promotes the expression of proteoglycans and calcium deposition in ATDC5 cells undergoing chondrogenic differentiation, and also promotes the expression of ATDC5 cell chondrogenic differentiation markers. Therefore, it has the potential to be formulated into a drug that can promote chondrogenic differentiation of chondrocytes, thereby promoting cartilage repair and regeneration for the treatment of osteoarthritis and rheumatoid arthritis.

Provided is a method for analyzing proteoglycan, which enables simple analysis of proteoglycan in a sample.　Specifically, provided is a method for analyzing proteoglycan, comprising immersing or adding a sample containing proteoglycan into an aqueous solution containing a salt to obtain a liquid composition; and adding an alcohol to the liquid composition at a specific, relatively low concentration to obtain a purified precipitate, which is then subjected to proteoglycan analysis.

The present application relates to the technical field of intervertebral disc degeneration treatment and drug delivery, and discloses an injectable oxynate sodium functionalized hydrogel microsphere loaded with TGFbeta3 and application, by loading glycolysis inhibitor SO in the GelMA microsphere matrix and post-adsorbing TGFbeta3, on the one hand, SO is used to inhibit the excessive active glycolysis in the degenerative microenvironment, reduce lactic acid accumulation and relieve inflammation, on the other hand, TGFbeta3 is used to effectively promote the synthesis of collagen and proteoglycan, both of which synergistically act from the two aspects of metabolic regulation and matrix synthesis, and jointly promote the recovery of intervertebral disc homeostasis, therefore, the oxynate sodium functionalized microsphere loaded with TGFbeta3 constructed by the present application can realize the synergistic treatment of multiple targets and multiple pathways by synchronously delivering metabolic regulators and synthesis promoters, so as to more effectively delay or reverse the intervertebral disc degeneration process, and finally achieve the beneficial effect of the double repair effect of simultaneously regulating abnormal glycolysis metabolism of degenerative nucleus pulposus cells and promoting extracellular matrix synthesis.

This invention discloses a Chlorella heptapeptide TGPLGSR with multi-target lipid-lowering activity, its preparation method, and its applications. The amino acid sequence of this heptapeptide is Thr-Gly-Pro-Leu-Gly-Ser-Arg. The preparation method includes: performing ultraviolet and electroporation combined mutagenesis on wild-type Chlorella proteoglycans to obtain a high-protein-content mutant algal strain; obtaining algal protein through fermentation and synergistic extraction and purification with alcohols; directionally digesting the protein with alkaline protease, followed by enriching the active peptide components through ultrafiltration and gel chromatography; and finally, screening the heptapeptide using liquid chromatography-mass spectrometry (LC-MS), computer-aided prediction, and molecular docking techniques. This heptapeptide exhibits potent inhibitory activity against pancreatic lipase and can dose-dependently reduce the accumulation of triglycerides and cholesterol in 3T3-L1 cells. Its mechanism involves multiple target pathways, including inhibition of MMP-9, activation of AMPK phosphorylation, and downregulation of PNLIP, and it can be used to develop lipid-lowering functional foods or health products.

The present invention provides a novel method that can improve or maintain muscle quantity or muscle strength, and a novel method that can prevent obesity, or lower body fat percentage, or lower body fat quantity, or lower fat removal quantity. The proteoglycan used in the present invention is obtained by a method for producing the proteoglycan, comprising the steps of immersing a biological sample comprising the proteoglycan in an aqueous solution of a surfactant and collecting the solution after the immersion.

The invention discloses application of an IGF2BP2-m6A-VCAN-TLR2 (Insulin-like Growth Factor 2BP2-m6A-VCAN-TLR2) signal axis in preparation of a medicine for treating lymphatic metastasis of intrahepatic cholangiocarcinoma. Aiming at the problems of unknown lymphatic metastasis mechanism and lack of effective targets of intrahepatic cholangiocarcinoma, the invention discovers and verifies that mRNA binding protein 2 of insulin-like growth factor 2 is modified by m6A to regulate and control the expression of pluripotent proteoglycan so as to activate a Toll-like receptor 2 signal, promote macrophages to secrete vascular endothelial growth factor C and drive a brand new pathway of lymphatic metastasis. Based on this, the invention provides an inhibitor targeting the signal axis, especially a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit migration, invasion and epithelial-mesenchymal transition of bile duct cancer cells, reduce macrophage secretion of vascular endothelial growth factors C, effectively inhibit tumor growth and lymphatic metastasis in a nude mouse popliteal lymph node metastasis model and a spontaneous bile duct cancer model, and present a synergistic effect when combined with gemcitabine and cis-platinum.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

When extracting PG from cartilage, other cartilage components such as collagen are extracted simultaneously and efficiently. [Solution] A method for producing a cartilage component mixture containing proteoglycans, comprising the steps of: immersing cartilage in an aqueous citric acid solution containing 0.01% by mass or more and less than 0.05% by mass at 30 to 80°C to obtain a cartilage component extract; and recovering cartilage components from the extract. .

The invention discloses preparation and application of a proteoglycan colloid material capable of rapidly stopping bleeding and promoting wound healing, and belongs to the field of biological materials. Basic amino acid rich in lysine or arginine is designed and expressed through molecular engineering, and then basic protein and hyaluronic acid with negative electricity are combined through a supramolecular assembly method to prepare a proteoglycan material with antibacterial ability. Then, recombinant mucoprotein rich in tyrosine is designed and expressed, and a DOPA adhesion group is formed through tyrosinase modification, so that the instant adhesion of the tissue adhesion material is enhanced. The amino acid of the basic protein remarkably enhances the interaction of various molecules of proteoglycan, meanwhile, the basic amino acid endows the tissue adhesive with excellent antibacterial ability, and the tissue adhesive provided by the invention has instant tissue adhesion performance, excellent biocompatibility and excellent antibacterial ability and hemostatic performance, and is suitable for being used in the field of medical instruments. The healing of different types of bleeding scenes and irregular wounds is facilitated.

The application discloses an IGF2BP2-m6A-VCAN-TLR2 signal axis in the preparation of a drug for treating intrahepatic cholangiocarcinoma lymphatic metastasis. In view of the problems of unknown intrahepatic cholangiocarcinoma lymphatic metastasis mechanism and lack of effective target, the application finds and verifies a new pathway that from insulin-like growth factor 2 mRNA binding protein 2, m6A modification regulates the expression of multi-functional proteoglycan, and then activates Toll-like receptor 2 signal, promotes macrophage secretion of vascular endothelial growth factor C and drives lymphatic metastasis. Based on this, the application provides an inhibitor targeting the signal axis, in particular, a small molecule compound 8010-8498. Experiments show that the compound can significantly inhibit cholangiocarcinoma cell migration, invasion and epithelial mesenchymal transition, reduce macrophage secretion of vascular endothelial growth factor C, and effectively inhibit tumor growth and lymphatic metastasis in a naked mouse popliteal lymph node metastasis model and a spontaneous cholangiocarcinoma model. The compound presents a synergistic effect in combination with gemcitabine and cisplatin.

The application discloses a pharmaceutical composition for promoting angiogenesis and tissue regeneration and application thereof. The pharmaceutical composition comprises a cysteine-rich acidic secretory protein, a biglycan and a collagen XV alpha 1 chain. The application can promote angiogenesis and improve the tissue regeneration efficiency of bone, cartilage and skin defect areas through a biomaterial system loaded with the three types of proteins.

Radiopharmaceuticals and conjugates targeting GPC3, as well as their compositions and uses, are provided herein. In one embodiment, a conjugate comprising a peptide having avidity to GPC3 and a metal chelating agent configured to bind to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. The conjugate described herein may further comprise a radionuclide. In one embodiment, a radiopharmaceutical comprising a peptide and a metal chelating agent binding to a radionuclide is provided herein. The conjugate described herein may further comprise a linker connecting the chelating agent and the peptide. Methods for treating cancer by administering the radiopharmaceuticals, conjugates, and compositions thereof are further provided herein.

The aim is to prevent and / or improve skin conditions that negatively affect skin appearance, such as wrinkles and sagging, by promoting the formation of cyclic collagen. [Solution] Screening was conducted on the expression of proteoglycan-related genes involved in proteoglycan formation, and it was found that rosehip extract or safflower extract increases the gene expression of persican and periostin, which are proteoglycan-related genes. Thus, rosehip extract or safflower extract was identified as a promoter of cyclic collagen formation.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

Provided is a method for analyzing proteoglycan, whereby proteoglycan in a sample can be easily analyzed. A sample containing proteoglycan is immersed or added to an aqueous solution containing a salt, and a purified precipitate obtained by adding an alcohol at a low specific concentration to the obtained liquid composition is subjected to proteoglycan analysis.

The invention belongs to the technical field of plasma protein markers, and discloses a plasma protein marker and a risk prediction system for a heart failure onset risk of a type 2 diabetes mellitus patient, and the protein marker combination is applied to preparation of a kit for predicting the heart failure onset risk of the type 2 diabetes mellitus patient. The protein marker combination comprises a C-C motif chemotactic factor 24, a C-C motif chemotactic factor 7, a carcino-embryonic antigen related cell adhesion molecule 6, a fiber gelling protein 1, a follistatin, a polypeptide N-acetylgalactosamino transferase 5, an ADP ribosylation factor binding protein GGA1, a kallikrein 4, a nerve bundle protein, renin, a plasma protease C1 inhibitor and cardiac troponin I, the brain natriuretic peptide comprises a brain natriuretic peptide precursor, an N-terminal brain natriuretic peptide precursor, apolipoprotein C1, tetramer connexin, a Mepin A beta subunit and multi-ligand proteoglycan-4. The invention further constructs a risk score and prediction model for predicting the attack risk of the heart failure of the type 2 diabetes mellitus patient based on the protein marker.

Provided herein are compositions comprising peptides that bind specifically to BΔg (deglycosylated brevican), and methods of use thereof to deliver therapeutic and diagnostic agents to brevican-expressing cells, e.g., cancerous cells, e.g., brain cancer cells, e.g., glioblastoma cells.

The present invention provides a method for manipulating the fucosylated glycan content on a recombinant protein.

The invention discloses an application of a calcium-reinforced layered network structure emulsion in preparation of a product for promoting calcium absorption and enhancing bone mineral density, and aims to solve the technical bottlenecks of low absorption rate and insufficient bone targeting of a traditional calcium supplement. According to the emulsion, the insoluble calcium salt is uniformly dispersed in an oil phase by utilizing the density difference between the insoluble calcium salt and the oil phase, and is embedded into a layered network structure formed by proteoglycan. Hydrophobic molecules or hydrophobic chain segments spontaneously gather to form a hydrophobic region, and free diffusion of water molecules and water-soluble ions is effectively prevented, so that solubilization and stable dispersion of insoluble calcium salt are realized. The obtained emulsion has good processing stability and tolerance, the absorption rate of calcium is remarkably improved, and the bone mineral density is favorably enhanced. The system can be used as a calcium fortifying preparation to realize on-line addition, the process is simple and convenient, the system is suitable for various foods such as dairy products, biscuits, ice cream and plant milk, and preparation and application of high-calcium nutritious foods are realized.

The invention relates to the technical field of bioinformatics and in vitro diagnosis, in particular to a prediction model, system and kit for risk assessment of acute myocardial infarction. The application systematically proves that the neutrophil-derived silk glycan (SRGN) is a key regulator of neutrophil inflammatory response in inflammatory cascade reaction after myocardial infarction, so that a model for predicting the risk of acute myocardial infarction through SRGN and neutrophil counting is determined; a corresponding kit and an evaluation system are designed according to the model. Compared with the prior art, the model and the related kit and evaluation system can quickly and accurately evaluate the risk of acute myocardial infarction in vitro.

The present disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells that target glypican 3.

Described herein are anti-Glypican 3 (GPC3) antibodies and binding proteins including such binding domains, as well as nucleic acids encoding the same. The disclosure also features methods of using such antibodies, antigen-binding fragments, binding proteins, and nucleic acid to treat various diseases, such as cancer (e.g., HCC).

In some aspects, disclosed are methods and compositions for disc regeneration and / or repair using one or more components from conditioned media from fibroblasts. In certain cases, conditioned media is obtained from fibroblasts stimulated with one or more opioid receptor antagonists and one or more toll-like receptor agonists. Conditioned media from fibroblasts may be provided in an effective amount to an individual in need thereof.

The invention belongs to the technical field of experimental model preparation, and provides a construction method of an in-vitro articular cartilage superficial layer injury model aiming at proteoglycan and collagenous fibers in a superficial cartilage layer (SFZ) in order to simulate cartilage surface component loss and structural damage in the early stage of OA morbidity, and the in-vitro articular cartilage superficial layer injury model is constructed by taking a pig knee joint cartilage as a material. A mixed solution of 0.01 mg / ml chymotrypsin and 0.5 mg / ml collagenase D is used as digestive enzyme, the surface of an in-vitro articular cartilage column is treated for 20 min, proteoglycan and collagenous fibers in SFZ are accurately destroyed, and an in-vitro articular cartilage superficial layer damage model is constructed; histological staining, microscopic observation and mechanical detection results all show that the method can cause SFZ structure damage and mechanical property reduction on the premise of not influencing deep tissues. The model has the advantages of simplicity and convenience in operation, low cost and controllable injury range, and provides a reliable experimental tool for research on early pathological mechanisms of osteoarthritis and exploration of related diagnosis and treatment means.

Described herein are biomarkers for the prediction of the risk of developing and / or having multiple sclerosis (MS), as well as staging / subtyping MS and methods for evaluating treatment protocols for MS and for assisting in the prognosis of MS. Also described herein are biomarkers associated with multiple sclerosis (MS), particular GLX molecules, and even more particular GLX-related glycosaminoglycans (GAGs) and GLX-related proteoglycans (PGs).

The purpose of the present invention is to provide a cartilage regeneration promoter. The cartilage regeneration promoter includes (A) hydroxycitric acid and / or a salt thereof, and (B) a sugar selected from the group consisting of chondroitin sulfate and a salt thereof, hyaluronic acid and a salt thereof, a proteoglycan, and the constituent sugar of the above sugars, and is capable of promoting cartilage regeneration.